A detailed history of High Vista Strategies LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, High Vista Strategies LLC holds 28,911 shares of CRNX stock, worth $1.56 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
28,911
Previous 35,237 17.95%
Holding current value
$1.56 Million
Previous $1.58 Million 6.46%
% of portfolio
0.58%
Previous 0.63%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$43.83 - $54.98 $277,268 - $347,803
-6,326 Reduced 17.95%
28,911 $1.48 Million
Q2 2024

Aug 14, 2024

BUY
$42.12 - $51.91 $814,516 - $1 Million
19,338 Added 121.63%
35,237 $1.58 Million
Q4 2023

Feb 14, 2024

BUY
$25.62 - $37.07 $407,332 - $589,375
15,899 New
15,899 $565,000
Q2 2023

Aug 14, 2023

SELL
$15.73 - $23.6 $245,734 - $368,679
-15,622 Reduced 32.38%
32,623 $587,000
Q1 2023

May 15, 2023

SELL
$15.31 - $21.1 $698,870 - $963,172
-45,648 Reduced 48.62%
48,245 $774,000
Q4 2022

Feb 14, 2023

BUY
$15.49 - $19.05 $28,594 - $35,166
1,846 Added 2.01%
93,893 $1.72 Million
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $1.07 Million - $1.32 Million
59,099 Added 179.37%
92,047 $1.81 Million
Q2 2022

Aug 15, 2022

SELL
$16.49 - $27.64 $185,974 - $311,723
-11,278 Reduced 25.5%
32,948 $614,000
Q1 2022

May 16, 2022

SELL
$17.15 - $28.31 $150,165 - $247,882
-8,756 Reduced 16.53%
44,226 $971,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $1.03 Million - $1.51 Million
52,982 New
52,982 $1.51 Million
Q4 2020

Feb 16, 2021

SELL
$12.08 - $17.46 $372,607 - $538,553
-30,845 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$13.62 - $17.66 $70,061 - $90,843
5,144 Added 20.01%
30,845 $483,000
Q2 2020

Aug 14, 2020

BUY
$13.04 - $23.23 $335,141 - $597,034
25,701 New
25,701 $450,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track High Vista Strategies LLC Portfolio

Follow High Vista Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Vista Strategies LLC with notifications on news.